Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (3103)	1/28/2016 12:38:46 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3202

The old trials, sure. They were single agent trials, designed to test for a direct anti-cancer effect. And CRC is the target with, to my knowledge, the least defined "inflammatory" subset..... infiltration is ass'd with better survival? There are two investigator-sponsored and ongoing breast trials with updated designs, one in inflammatory triple negative. The pancreatic trial is ongoing, obviously. I certainly do not belong to your subset which assumes that solid cancer trials are doomed. But I'm not a buyer of anything that has "priced in" sales expectations.